Kocitaf 50mg/200mg/25mg Tablet is unsafe to implement in patients with liver illness and will be prevented.This innovative drug is generally remaining explored for its prospective role in oncology, notably targeting various forms of most cancers. Researchers may also be investigating its software in autoimmune illnesses, aiming to leverage its spec